UTime Ltd (WTO) shares plummeted 93% on Wednesday following the announcement of a non-disclosure agreement with Bowen Therapeutics Inc. for the acquisition of Bowen’s laboratory at UMASS Medical School. The acquisition is part of UTime’s strategy to expand into the global vaccine market, with a focus on developing an mpox vaccine. Despite the significant drop, the potential for mpox vaccine development and the FDA approval process could influence future stock performance.